Pfizer stated on Tuesday that it has applied to the US Food and Drug Administration (FDA) for an emergency use authorization for its experimental antiviral Covid-19 tablet, also known as PF-07321332 or Paxlovid. There is an urgent need for life-saving treatment alternatives since this deadly disease has claimed the lives of almost 5 million people worldwide.
The high efficacy of PAXLOVID in a recent clinical trial and its potential to save lives and keep people out of the hospital if approved highlight the vital role that oral antiviral treatments could play in the fight against COVID-19.According to the company, the pill will be used in conjunction with an earlier antiviral medicine called ritonavir to treat mild to moderate Covid-19 in patients who are at a higher risk of hospitalization or death.
Merck and Ridgeback Biotherapeutics have also applied to the FDA for emergency use permission of molnupiravir, an antiviral tablet; an FDA advisory group will meet on November 30 to review the application. Molnupiravir, the first oral antiviral to be approved for the treatment of Covid-19, received approval from the UK Medicines and Healthcare Products Regulatory Agency earlier this month.